<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321074</url>
  </required_header>
  <id_info>
    <org_study_id>FG-506-01-IT-02</org_study_id>
    <nct_id>NCT00321074</nct_id>
  </id_info>
  <brief_title>Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts</brief_title>
  <acronym>PANTERA</acronym>
  <official_title>AN OPEN, MULTICENTRE, RANDOMISED PARALLEL GROUP CLINICAL STUDY TO COMPARE SAFETY AND EFFICACY OF TACROLIMUS (FK506) WITH MONOCLONAL ANTI-IL2R ANTIBODIES (DACLIZUMAB) VS TACROLIMUS (FK506) WITH STEROIDS AND EVALUATE PHARMACOKINETICS IN LIVER ALLOGRAFT RECIPIENTS RECEIVING SUBOPTIMAL LIVERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the safety and efficacy of two different tacrolimus
      based immunosuppressive regimens, one in combination with daclizumab, the other in
      combination with steroids, in recipients of suboptimal livers.

      Pharmacokinetics of tacrolimus and bile composition will be measured in a subgroup of
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, multicentre, 1:1 randomised, parallel group phase III study to compare safety and
      efficacy of tacrolimus (FK506) with monoclonal anti-IL2R antibodies (daclizumab) vs
      tacrolimus (FK506) with steroids and evaluate pharmacokinetics in liver allograft recipients
      receiving suboptimal livers.

      Patients receiving primary suboptimal liver allograft transplantation (from donors &gt; 65 years
      and/or liver macrosteatosis &gt;15%) will be randomised to one of the following treatment arms:

      Group I: steroid bolus (intraoperative) monoclonal anti-IL2R antibodies (daclizumab)
      induction tacrolimus Group II: steroid bolus (intraoperative) tacrolimus steroids
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of and time to first biopsy-proven and treatment requiring acute rejection</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>LIVER TRANSPLANTATION</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TACROLIMUS</intervention_name>
    <description>Immunosuppression</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Prograf, FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Adult patients scheduled to receive a liver transplant

          -  Donors older than 65 and/or has liver macrosteatosis &gt;15%

          -  Female patients of childbearing potential agree to maintain effective birth control
             during the study and must have negative pregnancy test at baseline

        Exclusion Criteria:

          -  Patient has previously received or is receiving an organ transplant other than liver,
             or a liver re-transplantation.

          -  Patient has significant, uncontrolled concomitant infections and/or severe diarrhea,
             vomiting, or active peptic ulcer

          -  Patient is receiving an auxiliary graft or a bio-artificial liver has been used.

          -  Any pathology or medical condition that can interfere with this protocol study
             proposal

          -  Other exclusion applies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <zip>24122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda</url>
    <description>Link to FDA website</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140557 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>August 25, 2014</last_update_submitted>
  <last_update_submitted_qc>August 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMMUNOSUPPRESSION</keyword>
  <keyword>TACROLIMUS</keyword>
  <keyword>MARGINAL LIVERS</keyword>
  <keyword>PHARMACOKINETICS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

